Ar-BIAN and Ar-BICAT Diimine Platinum Diphenyl Complexes
to a stirred solution of (N–N)PtPh2 (ca. 100 mg, depending on the
diimine, 0.14 mmol) in acetonitrile at 0 °C under an argon atmo-
sphere. The solution was stirred and gradually warmed to ambient
temperature. After 1 h the solvent was removed under vacuum, and
the resulting red-orange solid was washed several times with ether.
The product was recrystallized from a dichloromethane solution
layered with ether.
(75 MHz, CD2Cl2): δ = 144.4, 140.8, 139.9, 135.5, 133.0, 132.5,
131.2, 130.5, 129.7, 126.3, 125.6, 124.7, 120.5, 119.2, 21.5, 21.1, 3.7
ppm. 19F NMR (188 MHz, CD2Cl2): δ = –153.04, –153.10 (10BF4
–
–
and 11BF4 ) ppm. 195Pt NMR (107 MHz, CD2Cl2): δ = –3216 ppm.
C36H32BF4N3Pt (788.54): calcd. C 54.8, H 4.1, N 5.3; found C 53.8,
H 4.3, N 5.7. ESI MS: m/z = 701.1 [M+].
–
(4-MeC6H4-BIAN)PtPh(NCMe)+BF4– (3e·BF4 ): From 1e (100 mg,
1
(2,6-Me2C6H3-BIAN)PtPh(NCMe)+BF4
(3a·BF4 ): From 1a
–
–
0.14 mmol). Yield 58 mg (54%). H NMR (300 MHz, CD2Cl2): δ
(113 mg, 0.15 mmol). Yield 88 mg (73%). 1H NMR (300 MHz,
CD2Cl2): δ = 8.35 (d, J = 7.1 Hz, 1 H, AnHp), 8.33 (d, J = 7.1 Hz,
1 H, AnHp), 7.64 (dd, J = 8.3, J = 8.3 Hz, 1 H, AnHm), 7.54 (dd,
J = 8.3, J = 8.3 Hz, 1 H, AnHm), 7.44 (br., 3 H, ArH), 7.22 (t, J
= 8.3 Hz, 1 H, ArHp), 7.16 (d, J = 7.0 Hz, 1 H, AnHo), 7.09 (d, J
= 7.7 Hz, 2 H, ArHm), 6.89–6.87 (m, 2 H, PhHo), 6.74–6.71 (m, 3
H, PhHm,p), 6.69 (d, J = 7.2 Hz, 1 H, AnHo), 2.50 (s, 6 H, ArMe),
2.24 (s, 6 H, ArMe), 2.06 [s, 4J(Pt-H) = 10.3 Hz, 3 H, NCMe] ppm.
13C{1H} NMR (75 MHz, CD2Cl2): δ = 148.2, 142.2, 135.1, 133.7,
133.0, 132.2, 130.5, 130.4, 140.0, 129.6, 129.4, 129.1, 127.0, 125.6,
125.5, 125.2, 124.9, 18.0, 17.9, 3.2 ppm. 19F NMR (188 MHz,
= 8.30 (d, J = 8.2 Hz, 1 H, AnHp), 8.28 (d, J = 7.8 Hz, 1 H, AnHp),
7.62 (t, J = 7.8 Hz, 1 H, AnHm), 7.57–7.45 (m, 6 H, AnHo,m and
ArH), 7.11 (d, J = 8.0 Hz, 2 H, ArH), 6.93–6.85 (m, 5 H, ArH,
AnHo and PhHo), 6.74–6.72 (m, 3 H, PhHm,p), 2.57 (s, 3 H, ArMe),
2.36 (s, 3 H, ArMe), 2.20 (br. s, 3 H, NCMe) ppm. 13C{1H} NMR
(75 MHz, CD2Cl2): δ = 178.6, 171.4, 147.9, 142.4, 142.0, 140.5,
139.7, 135.8, 133.1, 132.5, 132.2, 130.9, 130.7, 130.2, 129.6, 127.2,
126.2, 125.9, 125.5, 125.1, 124.5, 122.8, 121.9, 21.4, 21.6, 3.8 ppm.
–
19F NMR (188 MHz, CD2Cl2): δ = –152.88, –152.93 (10BF4 and
11BF4 ) ppm. 195Pt NMR (107 MHz, CD2Cl2): δ = –3216 ppm.
–
C34H28BF4N3Pt (760.49): calcd. C 53.7, H 3.7, N 5.5; found C 51.3,
H 3.8, N 5.1. ESI MS: m/z = 673.1 [M+].
–
–
CD2Cl2): δ = –153.02, –153.07 (10BF4 and 11BF4 ) ppm. 195Pt
NMR (107 MHz, CD2Cl2): δ = –3170 ppm. C36H32BF4N3Pt
(788.54): calcd. C 54.8, H 4.1, N 5.3; found C 54.0, H 4.3, N 5.3.
ESI MS: m/z = 701.1 [M+].
(4-CF3C6H4-BIAN)PtPh(NCMe)+BF4– (3f·BF4 ): From 1f (100 mg,
–
1
0.12 mmol). Yield 60 mg (56%). H NMR (300 MHz, CD2Cl2): δ
= 8.34 (d, J = 6.8 Hz, 1 H, AnHp), 8.32 (d, J = 7.0 Hz, 1 H, AnHp),
8.06 (d, J = 8.4 Hz, 2 H, ArH), 7.82 (d, J = 6.2 Hz, 2 H, ArH),
7.64 (dd, J = 7.5, 8.2 Hz, 1 H, AnHm), 7.58–7.51 (m, 3 H, AnHm
and ArH), 7.39 (d, J = 7.3 Hz, 1 H, AnHo), 7.24 (d, J = 8.3 Hz, 2
H, ArH), 6.92 (d, J = 8.3 Hz, 1 H, AnHo), 6.86–6.84 (m, 2 H,
PhHo), 6.72–6.70 (m, 3 H, PhHm,p), 2.21 (s, 3 H, NCMe) ppm.
13C{1H} NMR (75 MHz, CD2Cl2): δ = 135.5, 133.7, 133.1, 132.3,
129.9, 127.9, 127.6, 127.0, 126.3, 125.9, 125.6, 124.8, 124.0, 123.0,
3.8 ppm. 19F NMR (188 MHz, CD2Cl2): δ = –62.65 (s, Ar-CF3),
(2,4,6-Me3C6H2-BIAN)PtPh(NCMe)+BF4 (3b·BF4 ): From 1b
(100 mg, 0.13 mmol). Yield 90 mg (85%). 1H NMR (300 MHz,
CD2Cl2): δ = 8.35 (d, J = 7.9 Hz, 1 H, AnHp), 8.33 (d, J = 7.6 Hz,
1 H, AnHp), 7.64 (dd, J = 7.4, 7.3 Hz, 1 H, AnHm), 7.54 (dd, J =
7.5, 7.2 Hz, 1 H, AnHm), 7.24 (br. s, 2 H, ArHm), 7.18 (d, J =
7.2 Hz, 1 H, AnHo), 6.89 (br. s, 2 H, ArHm), 6.89–6.85 (m, 2 H,
PhHo), 6.75–6.72 (m, 4 H, AnHo and PhHm,p), 2.47 (s, 3 H, Ar-
Mep), 2.45 (s, 6 H, ArMeo), 2.30 (s, 3 H, ArMep), 2.16 (s, 6 H,
ArMeo), 2.07 (s, 3 H, NCMe) ppm. 13C{1H} NMR (75 MHz,
CD2Cl2): δ = 178.9, 148.0, 140.2, 139.9, 139.4, 139.1, 135.3, 133.5,
132.8, 130.4, 130.3, 130.1, 129.9, 129.6, 128.8, 126.9, 125.7, 125.5,
124.9, 21.2, 21.1, 17.9, 17.2, 3.2 ppm. 19F NMR (188 MHz,
–
–
–
–
–63.02 (s, Ar-CF3), –152.35 and –152.40 (10BF4 and 11BF4 ) ppm.
195Pt NMR (107 MHz, CD2Cl2): δ = –3240 ppm. C34H22BF10N3Pt
(868.43): calcd. C 47.0, H 2.6, N 4.8; found C 46.2, H 2.7, N 4.9.
ESI MS: m/z = 781.0 [M+].
CD2Cl2): δ = –153.11, –153.16 (10BF4 and 11BF4 ) ppm. 195Pt
NMR (107 MHz, CD2Cl2): δ = –3164 ppm. C38H36BF4N3Pt
(816.60): calcd. C 55.9, H 4.4, N 5.2; found C 55.0, H 4.5, N 5.0.
ESI MS: m/z = 729.1 [M+].
–
–
–
–
(4-MeC6H4-BICAT)PtPh(NCMe)+BF4
(3g·BF4 ): From 1g
(100 mg, 0.15 mmol). Yield 89 mg (83%). 1H NMR (200 MHz,
CD2Cl2): δ = 7.43 (br., 4 H, ArH), 7.31–7.20 (m, 3 H, catechol-H),
7.14–7.08 (m, 1 H, catechol-H), 6.95 (br. d, J = 7.9 Hz, 2 H, ArH),
6.87 (br. d, J = 8.1 Hz, 2 H, ArH), 6.83–6.78 (m, 2 H, PhHo), 6.69–
6.63 (m, 3 H, PhHm,p), 2.47 (s, 3 H, ArMe), 2.26 (s, 3 H, ArMe),
(4-Br-2,6-Me2C6H2-BIAN)PtPh(NCMe)+BF4 (3c·BF4 ): From 1c
(100 mg, 0.11 mmol). Yield 71 mg (68%). 1H NMR (300 MHz,
CD2Cl2): δ = 8.41 (d, J = 8.4 Hz, 1 H, AnHp), 8.38 (d, J = 8.4 Hz,
1 H, AnHp), 7.69 (dd, J = 8.3, 8.3 Hz, 1 H, AnHm), 7.62 (br. s, 2
H, ArHm), 7.60 (dd, J = 8.3, 8.3 Hz, 1 H, AnHm), 7.24 (br. s, 2 H,
ArHm), 7.21 (d, J = 7.1 Hz, 1 H, AnHo), 6.86–6.77 (m, 6 H, AnHo
and PhHo,m,p), 2.49 (s, 6 H, ArMe), 2.21 (s, 6 H, ArMe), 2.19 (br.
s, 3 H, NCMe) ppm. 13C{1H} NMR (75 MHz, CD2Cl2): δ = 178.9,
172.7, 148.4, 141.5, 134.9, 134.2, 133.5, 132.4, 132.3, 132.1, 131.5,
130.6, 130.5, 127.3, 125.6, 125.2, 125.1, 124.9, 122.6, 122.2, 17.9,
17.8, 3.5 ppm. 19F NMR (188 MHz, CD2Cl2): δ = –152.61, –152.65
–
–
4
2.08 [s, J(195Pt-NCMe) = 13.9 Hz, 3 H, NCMe] ppm. 19F NMR
–
(188 MHz, CD2Cl2): δ = –152.15, 152.20 (10BF4– and 11BF4 ) ppm.
ESI MS: m/z = 655.2 [M+].
General Procedure for in situ Generation of (N–N)PtPh(η2-C6H6)+
–
(4a–g) as BF4 Salts: The appropriate (N-N)PtPh2 complex (ca.
5 mg, 7 µmol) was dissolved in CD2Cl2 (400 µL) and kept under
an inert atmosphere at –78 °C in an NMR tube. A pre-made mix-
ture of HBF4·Et2O (5–10 µL) in [D10]Et2O (80 µL) and CD2Cl2,
for a total volume of 300 µL, was then carefully layered on top of
the solution of 1 in CD2Cl2 and the tube with contents was main-
tained at –78 °C in a dry ice/acetone bath without mixing of the
layers. This procedure was used to minimize premature protonation
of the Pt complex 1. The tube was shaken to mix the layers immedi-
ately before it was transferred to the pre-cooled NMR probe at the
desired temperature. The low-temperature 1H NMR spectra indi-
cated clean conversion of compounds 1a–g into the corresponding
PtII phenyl π-benzene complexes 4a–g.
–
–
(10BF4 and 11BF4 ) ppm. 195Pt NMR (107 MHz, CD2Cl2): δ =
–3177 ppm. C36H30BBr2F4N3Pt (946.33): calcd. C 45.7, H 3.2, N
4.4; found C 44.7, H 3.2, N 4.2. ESI MS: m/z = 857.9, 859.9 [M+].
(3,5-Me2C6H3-BIAN)PtPh(NCMe)+BF4
(3d·BF4 ): From 1d
–
–
(100 mg, 0.14 mmol). Yield 82 mg (76%). 1H NMR (300 MHz,
CD2Cl2): δ = 8.30 (d, J = 8.2 Hz, 1 H, AnHp), 8.28 (d, J = 8.1 Hz,
1 H, AnHp), 7.62 (dd, J = 7.4, 8.2 Hz, 1 H, AnHm), 7.52 (dd, J =
7.5, 8.3 Hz, 1 H, AnHm), 7.47 (d, J = 7.1 Hz, 1 H, AnHo), 7.24 (br.
s, 1 H, ArHp), 7.15 (br. s, 2 H, ArHo), 7.02 (d, J = 7.1 Hz, 1 H,
(2,6-Me2C6H3-BIAN)PtPh(η2-C6H6)+BF4 (4a·BF4 ): 1H NMR
–
–
AnHo), 6.93 (br. s, 1 H, ArHp), 6.89–6.86 (m, 2 H, PhHo), 6.77– (500 MHz, CD2Cl2, –35 °C): δ = 8.29 (d, J = 8.3 Hz, 1 H, AnHp),
6.71 (m, 3 H, PhHm,p), 6.61 (br. s, 2 H, ArHo), 2.50 (s, 6 H, ArMe),
8.24 (d, J = 8.4 Hz, 1 H, AnHp), 7.51 (t, J = 7.9 Hz, 1 H, AnHm),
7.46 (t, J = 7.9 Hz, 1 H, AnHm), 7.40–7.37 (m, 3 H, ArH), 7.07 (s,
2.20 (s, 6 H, ArMe), 2.19 (s, 3 H, NCMe) ppm. 13C{1H} NMR
Eur. J. Inorg. Chem. 2010, 1381–1394
© 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjic.org
1391